Exscientia CEO Andrew Hopkins and Sanofi CEO Paul Hudson
Sanofi, Exscientia ink the next AI megadeal, signing terms on a $100M upfront pact with up to 15 drugs on the line
Drug R&D has for years had an abysmal track record of success, with the vast majority of drug candidates never making it to market. The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
